实时更新： Keymed Biosciences Inc. [2162.HK]

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.